GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

01

Dual Glucagon–GLP-1 Agonism (Survodutide) Produces Substantial Weight Loss in Obesity: NEJM| August 2026

Introduction: GLP-1–based therapies have transformed obesity management, but additional metabolic pathways may further improve treatment. Survodutide is a once-weekly dual glucagon receptor and GLP-1 receptor agonist, designed to...

02

Difference Between Barium Swallow and Timed Barium Swallow: GastroAGI | August 2026

Barium swallow – anatomy and morphology: A conventional barium swallow is primarily a dynamic fluoroscopic examination that evaluates the anatomy and movement of the esophagus. It helps identify...

03

Nasogastric Tubes in 2026: Use Them Selectively, Remove Them Early: JAMA Surgery August | 2026.

Key Takeaways NG tubes remain most valuable for decompression, particularly in small-bowel obstruction (SBO), severe gastric distension, vomiting, ileus, or impaired gastrointestinal propulsion. Why decompression works: the gastrointestinal...

04

A Novel Oral Nonpeptide GLP-1 Agonist (HRS-7535) Improves Glycemic Control in Type 2 Diabetes: JAMA Network Open | August 2026

Introduction: Oral GLP-1 receptor agonists could overcome the inconvenience of injections, but currently available oral semaglutide requires specific fasting and administration conditions. HRS-7535 is a novel once-daily nonpeptide...

05

Nicotine Pouches: JAMA | July 2026

Introduction: Nicotine pouches are an increasingly popular smokeless oral nicotine product marketed as an alternative to cigarettes and other tobacco products. This review summarises their composition, health effects,...

06

Dopamine Beyond Reward. JAMA| May 2026

This review redefines dopamine (DA) signaling beyond its classical role in reward processing, positioning dopaminergic circuits as central regulators of feeding behavior, metabolic sensing, and energy homeostasis. The...

07

Gut–Heart Axis: Gut | May 2026

Introduction Atherosclerosis has traditionally been viewed as a lipid-driven disease. However, emerging evidence highlights a critical role of chronic inflammation and immune activation, with the gut microbiota now...

08

Bleeding Risk with Apixaban vs. Rivaroxaban: NEJM March 2026

Clinical Summary In this randomized international trial (COBRRA), investigators compared the bleeding risk of apixaban vs. rivaroxaban in patients with acute venous thromboembolism (VTE), including pulmonary embolism and...

09

ACG 2025

The American College of Gastroenterology (ACG) 2025 meeting is a prominent annual event where groundbreaking research, clinical studies, and advancements in gastroenterology are presented. At the ACG 2025...

10

Alcohol Use Disorder (AUD) with Alcohol-Related Liver Disease (ArLD) - Pharmacology

Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ArLD) often coexist, presenting a complex clinical challenge that requires careful consideration of pharmacological treatment. Below is a detailed explanation...

Previous
123456
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer